Biz Break: Gilead’s new hepatitis C drug produces huge sales in debut quarter

Posted on by

Today: Gilead Sciences demolishes earnings expectations thanks to powerful sales of breakthrough hepatitis C drug Sovaldi.

Read the original post by Inside Bay Area